Gedeon Richter upgrades 2026 guidance on strong delivery

Gedeon Richter Plc. reported its financial results for the third quarter and first nine months of 2026 on Tuesday, raising its full-year revenue and profit guidance.

The Budapest-based pharmaceutical company said its pharma revenues at constant exchange rates grew 11.7% in the first nine months of 2026. Reported pharma revenues increased 2.6% to HUF 686.5bn, affected by approximately 9 percentage points of currency headwind.

Clean EBIT for pharma at constant exchange rates rose 25% in the nine-month period, while reported Clean EBIT increased 8% to HUF 229.9bn.

The company attributed the growth to its BIO division approaching breakeven, continued strength in cariprazine, and lower operating expenses from efficiency initiatives.

Net profit attributable to the owners reached HUF 174.9bn in the first nine months, up 7.1% from the prior year. Free cash flow before mergers and acquisitions increased 12% to a record HUF 223bn.

The company’s CNS segment revenues grew 19% at constant exchange rates, driven by Vraylar sales, which reached $3.04bn at AbbVie, up 17% from last year. Reagila sales jumped 37% at constant exchange rates.

Women’s Healthcare sales grew 11% at constant exchange rates in the nine-month period, with growth accelerating to 19% in the third quarter. Ryeqo, Lenzetto, and Drovelis were the main contributors.

BIO revenues increased 35% at constant exchange rates, supported by biosimilar products and CDMO revenues.

Gedeon Richter upgraded its 2026 revenue guidance to above 10% growth at constant exchange rates and raised its Clean EBIT guidance to high-teens growth.